155 related articles for article (PubMed ID: 10464027)
1. Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists.
Tamiz AP; Cai SX; Zhou ZL; Yuen PW; Schelkun RM; Whittemore ER; Weber E; Woodward RM; Keana JF
J Med Chem; 1999 Aug; 42(17):3412-20. PubMed ID: 10464027
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors.
Tamiz AP; Whittemore ER; Zhou ZL; Huang JC; Drewe JA; Chen JC; Cai SX; Weber E; Woodward RM; Keana JF
J Med Chem; 1998 Aug; 41(18):3499-506. PubMed ID: 9719603
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.
Whittemore ER; Ilyin VI; Woodward RM
J Pharmacol Exp Ther; 1997 Jul; 282(1):326-38. PubMed ID: 9223571
[TBL] [Abstract][Full Text] [Related]
4. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
Williams K
Mol Pharmacol; 1993 Oct; 44(4):851-9. PubMed ID: 7901753
[TBL] [Abstract][Full Text] [Related]
5. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
Ilyin VI; Whittemore ER; Guastella J; Weber E; Woodward RM
Mol Pharmacol; 1996 Dec; 50(6):1541-50. PubMed ID: 8967976
[TBL] [Abstract][Full Text] [Related]
6. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines.
Wright JL; Gregory TF; Bigge CF; Boxer PA; Serpa K; Meltzer LT; Wise LD; Cai SX; Hawkinson JE; Konkoy CS; Whittemore ER; Woodward RM; Zhou ZL
J Med Chem; 1999 Jul; 42(13):2469-77. PubMed ID: 10395488
[TBL] [Abstract][Full Text] [Related]
7. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor.
Cai SX; Kher SM; Zhou ZL; Ilyin V; Espitia SA; Tran M; Hawkinson JE; Woodward RM; Weber E; Keana JF
J Med Chem; 1997 Feb; 40(5):730-8. PubMed ID: 9057859
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (+/-)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype.
Guzikowski AP; Tamiz AP; Acosta-Burruel M; Hong-Bae S; Cai SX; Hawkinson JE; Keana JF; Kesten SR; Shipp CT; Tran M; Whittemore ER; Woodward RM; Wright JL; Zhou ZL
J Med Chem; 2000 Mar; 43(5):984-94. PubMed ID: 10715162
[TBL] [Abstract][Full Text] [Related]
10. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission.
Frizelle PA; Chen PE; Wyllie DJ
Mol Pharmacol; 2006 Sep; 70(3):1022-32. PubMed ID: 16778008
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site.
Cai SX; Zhou ZL; Huang JC; Whittemore ER; Egbuwoku ZO; Lü Y; Hawkinson JE; Woodward RM; Weber E; Keana JF
J Med Chem; 1996 Aug; 39(17):3248-55. PubMed ID: 8765507
[TBL] [Abstract][Full Text] [Related]
12. Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.
Avenet P; Léonardon J; Besnard F; Graham D; Frost J; Depoortere H; Langer SZ; Scatton B
Eur J Pharmacol; 1996 Jan; 296(2):209-13. PubMed ID: 8838458
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of novel NR2B selective NMDA receptor antagonists.
Kiss L; Cheng G; Bednar B; Bednar RA; Bennett PB; Kane SA; McIntyre CJ; McCauley JA; Koblan KS
Neurochem Int; 2005 May; 46(6):453-64. PubMed ID: 15769547
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.
Gill R; Alanine A; Bourson A; Buttelmann B; Fischer G; Heitz MP; Kew JN; Levet-Trafit B; Lorez HP; Malherbe P; Miss MT; Mutel V; Pinard E; Roever S; Schmitt M; Trube G; Wybrecht R; Wyler R; Kemp JA
J Pharmacol Exp Ther; 2002 Sep; 302(3):940-8. PubMed ID: 12183650
[TBL] [Abstract][Full Text] [Related]
15. Inducible expression and pharmacological characterization of recombinant rat NR1a/NR2A NMDA receptors.
Kurkó D; Dezso P; Boros A; Kolok S; Fodor L; Nagy J; Szombathelyi Z
Neurochem Int; 2005 Apr; 46(5):369-79. PubMed ID: 15737435
[TBL] [Abstract][Full Text] [Related]
16. Antagonist properties of polyamines and bis(ethyl)polyamines at N-methyl-D-aspartate receptors.
Igarashi K; Williams K
J Pharmacol Exp Ther; 1995 Mar; 272(3):1101-9. PubMed ID: 7891322
[TBL] [Abstract][Full Text] [Related]
17. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
Hess SD; Daggett LP; Crona J; Deal C; Lu CC; Urrutia A; Chavez-Noriega L; Ellis SB; Johnson EC; Veliçelebi G
J Pharmacol Exp Ther; 1996 Aug; 278(2):808-16. PubMed ID: 8768735
[TBL] [Abstract][Full Text] [Related]
18. Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors.
Kloda A; Clements JD; Lewis RJ; Adams DJ
Mol Pharmacol; 2004 Jun; 65(6):1386-96. PubMed ID: 15155832
[TBL] [Abstract][Full Text] [Related]
19. Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit.
Chaperon F; Müller W; Auberson YP; Tricklebank MD; Neijt HC
Behav Pharmacol; 2003 Sep; 14(5-6):477-87. PubMed ID: 14501261
[TBL] [Abstract][Full Text] [Related]
20. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites.
Christie JM; Jane DE; Monaghan DT
J Pharmacol Exp Ther; 2000 Mar; 292(3):1169-74. PubMed ID: 10688637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
